Early Initiation as Standard of Care: Meeting lactation goals in healthy and at-risk populations
Wednesday, 1 December 2021
Exclusive at-breast feeding to initiate lactation is the gold standard in the healthy term infant. However, due to a myriad of potential infant or maternal conditions, early and exclusive at-breast feeding may not be possible or effective. In some vulnerable populations, such as late preterm, this lack of effective breastfeeding may not be recognized, resulting in delayed or impaired milk production. This talk will cover the evidence behind appropriate lactation initiation, especially in at-risk populations, and how we can best support parents to meet their lactation goals.
- Lactation physiology in the transition from pregnancy to the early postpartum period and how it may be influenced by initiation behaviours
- Discuss common maternal and infant risk factors that impact lactation initiation and long term milk supply and how they may be mitigated
- Share the evidence for a proactive approach to lactation to facilitate lactation success in healthy as well as at-risk populations
Date: 1 December 2021
Duration : 1 hour
Time: 20:00 – 21:00 Central European Time (13:00 – 14:00 Central Standard Time)
Rebecca Hoban MD, MPH
Dr Rebecca Hoban is a staff neonatologist and the Director of Breastfeeding Medicine at The Hospital for Sick Children (“SickKids”) in Toronto, and an Associate Professor of Paediatrics at the University of Toronto. Dr Hoban graduated from Indiana University School of Medicine and completed a paediatric residency at Cincinnati Children’s Hospital, a neonatal-perinatal medicine fellowship at Tufts University, and a MPH at Harvard before joining the Neonatology and Human Milk Research team at Rush University Medical Center in Chicago. Dr Hoban joined SickKids in 2017 as neonatology staff, with a focus on human milk. Current projects include improving mother’s milk provision in the NICU, milk biomarkers to predict lactation success, inflammatory markers in human milk, and fresh milk as potential stem cell therapy in premature infants with intraventricular haemorrhage.